专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06169194A High surface density covalent immobilization of oligonucleotide monolayers using a 1-(thiotrifluoroacetato)-11-(trichlorososilyl)-undecane linker 失效
标题翻译：使用1-（三（三氟乙酰））-11-（三氯硅烷基） - 十一烷接头的高密度共价固定寡核苷酸单层
公开(公告)号：US06169194A
公开(公告)日：2001-01-02
申请号：US08951448
申请日：1997-10-16
申请人： Michael Thompson , Mark E. McGovern
发明人： Michael Thompson , Mark E. McGovern
IPC分类号： C07F712
CPC分类号： B82Y30/00 , B01J20/3242 , B32B17/10688 , B82Y5/00 , B82Y15/00 , C03C17/30 , C03C17/3405 , C07B2200/11 , C07H21/00 , Y10S977/702 , Y10S977/902 , Y10S977/92 , Y10S977/924 , Y10S977/958
摘要： Oligonucleotides and other biomolecules are immobilized in high density on solid substrates through covalent forces using either a permanent thioether bond, or a chemoselectively reversible disulfide bond to a surface thiol. Substrates which have hydroxyl groups on their surfaces can be first silanized with a trichlorosilane containing 2-20 carbon atoms in its hydrocarbon backbone, terminating in a protected thiol group. The oligonucleotides or other biomolecules are first connected to a tether consisting of a hydrocarbon or polyether chain of 2-20 units in length which terminates in a thiol group. This thiol may be further modified with a halobenzylic-bifunctional water soluble reagent which allows the conjugate to be immobilized onto the surface thiol group by a permanent thioether bond. Alternatively, the oligonucleotide-tether-thiol group can be converted to a pyridyldisulfide functionality which attaches to the surface thiol by a chemoselectively reversible disulfide bond. The permanently bound oligonucleotides are immobilized in high density compared to other types of thiol functionalized silane surfaces and to the avidin-biotin method.
摘要翻译：寡核苷酸和其他生物分子通过共价力使用永久硫醚键或与表面硫醇的化学选择性可逆二硫键以高密度固定在固体基质上。在其表面上具有羟基的底物可以首先在其烃骨架中用含有2-20个碳原子的三氯硅烷硅烷化，终止于受保护的硫醇基团。寡核苷酸或其他生物分子首先连接到由长度为2-20单位的烃或聚醚链组成的系链，其终止于硫醇基团。该硫醇可以用卤代苄基双功能水溶性试剂进一步改性，其允许缀合物通过永久硫醚键固定在表面硫醇基上。或者，寡核苷酸 - 系链 - 硫醇基团可以转化成通过化学选择性可逆的二硫键附着于表面硫醇的吡啶基二硫键官能团。与其他类型的硫醇官能化硅烷表面和抗生物素蛋白 - 生物素方法相比，永久结合的寡核苷酸以高密度固定。

2. 发明授权

US06369103B1 Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor 失效
标题翻译：使用HMG CoA还原酶抑制剂预防或降低发生心血管事件风险的方法
公开(公告)号：US06369103B1
公开(公告)日：2002-04-09
申请号：US08182471
申请日：1994-01-18
申请人： Bruce D. Behounek , Mark E. McGovern , Adeoye Y. Olukotun
发明人： Bruce D. Behounek , Mark E. McGovern , Adeoye Y. Olukotun
IPC分类号： A61K31265
CPC分类号： A61K31/662 , A61K31/00 , A61K31/22 , A61K31/34 , A61K31/365 , A61K31/366 , A61K31/38 , A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/415 , A61K31/66
摘要： A method is provided for preventing or reducing the risk of onset of a cardiovascular event by administering an HMG CoA reductase inhibitor such as pravastatin, to a patient which has one or more risk factors for a coronary and/or cerebrovascular event such as hypercholesterolemia.
摘要翻译：提供了一种通过向具有一种或多种冠状动脉和/或脑血管事件（例如高胆固醇血症）的危险因素的患者施用诸如普伐他汀的HMG CoA还原酶抑制剂来预防或降低心血管事件发作风险的方法。

3. 发明授权

US5691375A Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor 失效
标题翻译：使用HMG CoA还原酶抑制剂预防或降低发生心血管事件风险的方法
公开(公告)号：US5691375A
公开(公告)日：1997-11-25
申请号：US448211
申请日：1995-05-23
申请人： Bruce D. Behounek , Mark E. McGovern , Adeoye Y. Olukotun
发明人： Bruce D. Behounek , Mark E. McGovern , Adeoye Y. Olukotun
IPC分类号： A61K45/00 , A61K31/00 , A61K31/22 , A61K31/34 , A61K31/365 , A61K31/366 , A61K31/38 , A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/415 , A61K31/66 , A61P3/06 , A61P3/08 , A61P3/10 , A61P9/00 , A61P9/08 , A61P9/10 , A61P43/00 , A61K31/21
CPC分类号： A61K31/662 , A61K31/00 , A61K31/22 , A61K31/34 , A61K31/365 , A61K31/366 , A61K31/38 , A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/415 , A61K31/66
摘要： A method is provided for preventing or reducing the risk of onset of a cardiovascular event by administering an HMG CoA reductase inhibitor such as pravastatin, to a patient which has one or more risk factors for a coronary and/or cerebrovascular event such as hypercholesterolemia.
摘要翻译：提供了一种通过向具有一种或多种冠状动脉和/或脑血管事件（例如高胆固醇血症）的危险因素的患者施用诸如普伐他汀的HMG CoA还原酶抑制剂来预防或降低心血管事件发作风险的方法。

4. 发明授权

US5674893A Method for preventing reducing or risk of onset of cerebrovascular events employing an HMG CoA reductase inhibitor 失效
标题翻译：使用HMG CoA还原酶抑制剂预防脑血管事件降低或发生风险的方法
公开(公告)号：US5674893A
公开(公告)日：1997-10-07
申请号：US670919
申请日：1996-06-26
申请人： Bruce D. Behounek , Mark E. McGovern , Adeoye Y. Olukotun
发明人： Bruce D. Behounek , Mark E. McGovern , Adeoye Y. Olukotun
IPC分类号： A61K45/00 , A61K31/00 , A61K31/22 , A61K31/34 , A61K31/365 , A61K31/366 , A61K31/38 , A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/415 , A61K31/66 , A61P3/06 , A61P3/08 , A61P3/10 , A61P9/00 , A61P9/08 , A61P9/10 , A61P43/00 , A61K31/35
CPC分类号： A61K31/662 , A61K31/00 , A61K31/22 , A61K31/34 , A61K31/365 , A61K31/366 , A61K31/38 , A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/415 , A61K31/66
摘要： A method is provided for preventing or reducing the risk of onset of a cardiovascular event by administering an HMG CoA reductase inhibitor such as pravastatin, to a patient which has one or more risk factors for a coronary and/or cerebrovascular event such as hypercholesterolemia.
摘要翻译：提供了一种通过向具有一种或多种冠状动脉和/或脑血管事件（例如高胆固醇血症）的危险因素的患者施用诸如普伐他汀的HMG CoA还原酶抑制剂来预防或降低心血管事件发作风险的方法。

5. 依法登记的发明

USH1286H Method for treating peripheral atherosclerotic disease employing a cholesterol lowering drug, an ACE inhibitor, or a combination thereof 失效
标题翻译：用于治疗使用胆固醇降低药物，ACE抑制剂或其组合的外周性甲状旁腺疾病的方法
公开(公告)号：USH1286H
公开(公告)日：1994-02-01
申请号：US599570
申请日：1990-10-18
申请人： Martin Eisman , Mark E. McGovern
发明人： Martin Eisman , Mark E. McGovern
IPC分类号： A61K45/00 , A61K31/00 , A61K31/12 , A61K31/22 , A61K31/34 , A61K31/365 , A61K31/38 , A61K31/401 , A61K31/415 , A61K31/66 , A61K31/785 , A61K38/55 , A61P9/10 , A61K31/675 , A61K31/225 , A61K31/40
CPC分类号： A61K31/785 , A61K31/00 , A61K31/12 , A61K31/22 , A61K31/365 , A61K31/401 , A61K31/66 , A61K31/19 , A61K31/10 , A61K2300/00
摘要： A method is provided for treating peripheral atherosclerotic disease (arteriosclerosis obliterans) and/or intermittent claudication employing a cholesterol lowering drug such as an HMG CoA reductase inhibitor alone and/or an inhibitor of the enzyme squalene synthetase and optionally a pharmaceutical which reduces serum cholesterol by a mechanism other than inhibiting production of the enzyme HMG CoA reductase or the enzyme squalene synthetase, for example, probucol or gemfibrozil; employing an ACE inhibitor alone such as captopril or ceranapril; or a combination of a cholesterol lowering drug and an ACE inhibitor.
摘要翻译：提供一种用于治疗外周动脉粥样硬化疾病（闭塞性动脉硬化症）和/或单独使用降胆固醇药物如HMG CoA还原酶抑制剂和/或酶角鲨烯合成酶抑制剂的间歇性跛行的方法，以及任选的降低血清胆固醇的药物除抑制酶HMG CoA还原酶或酶角鲨烯合成酶例如普罗布考或吉非贝齐之外的机制; 单独使用ACE抑制剂，如卡托普利或西奈普利; 或胆固醇降低药物与ACE抑制剂的组合。

6. 发明授权

US5140012A Method for preventing onset of restenosis after angioplasty employing pravastatin 失效
标题翻译：预防持续性放射治疗后抑郁症的方法
公开(公告)号：US5140012A
公开(公告)日：1992-08-18
申请号：US532009
申请日：1990-05-31
申请人： Mark E. McGovern , Miguel A. Ondetti , Henry Y. Pan
发明人： Mark E. McGovern , Miguel A. Ondetti , Henry Y. Pan
IPC分类号： A61K31/22 , A61K31/365 , A61K31/425 , A61K31/47 , A61K31/55 , A61K31/675 , A61K31/685 , A61K38/00 , A61K38/55 , A61K45/06 , A61P9/08 , A61P9/10 , A61P43/00 , C07C59/46
CPC分类号： A61K31/22 , A61K31/401 , A61K45/06
摘要： A method is provided for preventing or reducing the risk of restenosis following angioplasty by administering pravastatin alone or in combination with an ACE inhibitor such as captopril or ceranapril, prior to, during and/or after angioplasty.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式